Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Amgen logo
AmgenAMGN
$246.43B+9.9%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s enterprise value?
Oruka Therapeutics, Inc. (ORKA) reported enterprise value of $2.38B in Q1 2026.
How has Oruka Therapeutics, Inc.'s enterprise value changed year-over-year?
Oruka Therapeutics, Inc.'s enterprise value increased by 690.1% year-over-year, from $301.51M to $2.38B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.